Clinical Trial Update: Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated different doses of SAR110894 on cognition in patients with mild to moderate Alzheimer's disease who are on donepezil.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAR110894

Snippet

Sponsor: Sanofi | Conditions: Dementia Alzheimer's Type | Phase 2 | Status: COMPLETED